{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-007328","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2022-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.134003+00:00","generated_at":"2026-06-26T21:23:03.340580+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pulmatrix reports positive Phase 1b top-line data for PUR1800 in stable COPD","bullets":["PUR1800 well-tolerated with no safety signals in 18-subject Phase 1b study.","Preliminary PK shows low and consistent systemic exposure via oral inhalation.","Company expects to advance PUR1800 to Phase 2 studies for AECOPD.","Results to be submitted at a medical conference later in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-007328","json":"https://secwatch.observer/filing/0001493152-22-007328.json","markdown":"https://secwatch.observer/filing/0001493152-22-007328.md","text":"https://secwatch.observer/filing/0001493152-22-007328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222007328/0001493152-22-007328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222007328/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:23:03.340580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}